Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Alkermes plc

Navigating SG&A Expenses: A Tale of Two Biopharma Giants

In the competitive landscape of biopharmaceuticals, effective cost management is crucial. Over the past decade, Alkermes plc and United Therapeutics Corporation have demonstrated distinct strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alkermes plc saw a remarkable 245% increase in SG&A expenses, peaking in 2023. This upward trend reflects their aggressive market expansion and investment in operational infrastructure. In contrast, United Therapeutics Corporation maintained a more stable trajectory, with a modest 25% increase over the same period, indicating a focus on efficiency and cost control. The year 2018 marked a pivotal point for United Therapeutics, with a significant dip in expenses, possibly due to strategic restructuring. These insights underscore the diverse approaches within the industry, offering valuable lessons in balancing growth and fiscal prudence.